Indication: Breast Cancer

A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE

Hormone receptor-positive, HER2-negative

Sub-indication: Adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer

Line of Therapy: High Risk Adjuvant

Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: Novartis Pharmaceuticals Corp

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.